Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer

Neoplasia

Volumn 13, Issue 2, 2011, Pages 167-179

  Kim, Sun Jin ^a   Kim, Jang Seong ^a   Kim, Seung Wook ^a   Brantley, Emily ^a   Yun, Seok Joong ^a   He, Junqin ^a   Maya, Marva ^a   Zhang, Fahao ^a   Wu, Qiuyu ^a   Lehembre, François ^a   Regenass, Urs ^b   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MODEL; CANCER SIZE; CELL STRAIN; CELL STRAIN IGROV1; CELL STRAIN SKOV3IP1; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 79951501975     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10806     Document Type: Article

References (87)

1. Jemal A, Siegal R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics. CA Cancer J Clin 59, 225-249.
2. Cannistra SA (1993). Cancer of the ovary. N Engl J Med 329, 1550-1559.
3. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, et al. (2003). A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovariancancer. J Natl Cancer Inst 9, 1320-1329.
4. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, and Davidson M (1996). Cyclophosphamide and cisplatincompared with paclitaxel and cisplatin in patients with stage III and stage IVovarian cancer. N Engl J Med 334, 1-6.
5. Bookman MA, McGuire WP III, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, and Ozols RF (1996). Carboplatinand paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14, 1895-1902.
6. Gore ME (2001). Treatment of relapsed epithelial ovarian cancer. In American Society of Clinical Oncology 2001 Education Book. American Society of Clinical Oncology, Alexandria, VA. pp. 468-476.
7. Fidler IJ (1995). Modulation of the organ microenvironment for the treatmentof cancer metastasis. J Natl Cancer Inst 87, 1588-1592.
8. Kim SJ, Uehara H, Karashima T, Sheperd DL, Killion JJ, and Fidler IJ (2003). Blockade of epidermal growth factor receptor signaling in tumor cells and tumorassociatedendothelial cells for therapy of and rogen-independent human prostatecancer growing in the bone of nude mice. Clin Cancer Res 9, 1200-1210.
9. Levin ER (1995). Endothelins. N Engl J Med 333, 356-363.
10. Masaki T (2000). The endothelin family: an overview. J Cardiovasc Pharmacol 35, S3-S5.
11. Bloch KD, Friedrich SP, Lee ME, Eddy RL, Shows TB, and Quertermous T (1989). Structural organization and chromosomal assignment of the gene encodingendothelin. J Biol Chem 264, 10851-10857.
12. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, and Sirois P (1993). Growth regulatory properties of endothelins. Peptides 14, 385-399.
13. Goldie RG (1999). Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 26, 145-148.
14. Remuzzi G, Perico N, and Benigni A (2002). New therapeutics that antagonizeendothelin: promises and frustrations. Nat Rev Drug Discov 1, 986-1000.
15. Opgenorth TJ (1995). Endothelin receptor antagonism. Adv Pharmacol 33, 1-65.
16. Lusher TF and Barton M (2000). Endothelins and endothelin receptor antagonists:therapeutic considerations for a novel class cardiovascular drugs. Circulation 102, 1434-1440.
17. Clozel M (2000). Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol 35, S65-S68.
18. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, et al. (2004). Endothelin-1promotes myofibroblasts induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhancedcontractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15, 2707-2719.
19. Yang Z, Krasnici N, and Lüscher TF (1999). Endothelin-1 potentiates humansmooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 100, 5-8.
20. Hocher B, Schwarz A, Fagan KA, Thöne-Reineke C, El-Hag K, Kusserow H, Elitok S, Bauer C, Neumayer H-H, Rodman DM, et al. (2000). Pulmonary fibrosisand chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 23, 19-26.
21. Nelson J, Bagnato A, Battistini B, and Nisen P (2003). The endothelin axis:emerging role in cancer. Nature Rev Cancer 3, 110-116.
22. Spinella F, Garrafa E, Di Castro V, Rosano L, Nicotra MR, Caruso A, Natali PG, and Bagnato A (2009). Endothelin-1 stimulates lymphatic endothelial cellsand lymphatic vessels to grow and invade. Cancer Res 69, 2669-2676.
23. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, Grégoire V, Balligand J-L, and Feron O (2004). Endothelin-1 is a critical mediator of mitogenictone in tumor arterioles: implications for cancer treatment. Cancer Res 64, 3209-3214.
24. Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, and Bagnato A (2005). Endothelin-1 promotes epithelial-to-mesenchymaltransition in human ovarian cancer cells. Cancer Res 65, 11649-11657.
25. Rosanò L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, and Bagnato A (2001). Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61, 8340-8346.
26. Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, and Horowitz JC (2009). Endothelin-1 and transforming growth factor-β1 independentlyinduce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol 41, 484-493.
27. Pristivishalil G and Nelson JB (2000). Endothelium-derived factors as paracrinemediators of prostate cancer progression. Prostate 44, 44-77.
28. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, and Simons JW (1996). Endothelin-1 production and decreased endothelin Breceptor expression in advanced prostate cancer. Cancer Res 56, 663-668.
29. Ahmed SI, Thompson J, Coulson JM, and Woll PJ (2000). Studies on the expressionof endothelin, its receptor subtypes, and converting enzymes in lungcancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22, 422-431.
30. Zhao YD, Springall DR, Hamid Q, Levene M, and Polak JM (1995). Localizationand characterization of endothelin-1 receptor binding in the blood vesselsof human pulmonary tumors. J Cardiovasc Pharmacol 26(suppl 3), S341-S345.
31. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, and Taylor I (2001). Increased endothelin-1 in colorectal cancer and reductionof tumour growth by ET(A) receptor antagonism. Br J Cancer 85, 1759-1763.
32. Eberl LP, Valdenaire O, Saintgiorgio V, Jeannin JF, and Juillerat-Jeanneret L (2000). Endothelin receptor blockade potentiates Fas L-induced apoptosis inrat colon carcinoma cells. Int J Cancer 86, 182-187.
33. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD, and Nelson JB (2007). Endothelin-1 promotes cell survival in renal cell carcinomathrough the ET(A) receptor. Cancer Lett 246, 139-148.
34. Venuti A, Salani D, Manni V, Poggiali F, and Bagnato A (2000). Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma:new potential targets for anticancer therapy. FASEB J 14, 2277-2283.
35. Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, and Venuti A (2002). Growth inhibition of cervix carcinoma cells in vivo byendothelin A receptor blockade. Cancer Res 62, 6381-6384.
36. Pagotto U, Arzberger T, Hopfner U, Sauer J, Renner U, Newton CJ, Lange M, Uhl E, Weindl A, and Stalla GK (1995). Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoralgrowth. J Clin Invest 96, 2017-2025.
37. Harland SP, Kuc RE, Pickard JD, and Davenport AP (1998). Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinityfor the selective antagonist PD156707. Neurosurgery 43, 890-898, discussion898-899.
38. Egidy G, Eberl LP, Valdenaire OV, Irmler M, Majdi R, Diserens A-C, Fontana A, Janzer R-C, Pinet F, and Juillerat-Jeanneret L (2000). The endothelin systemin human glioblastoma. Lab Invest 80, 1681-1689.
39. Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, and Bagnato A (2007). ZD4054, a specific antagonist of the endothelin A receptor, inhibitstumor growth and enhances paclitaxel activity in human ovarian carcinomain vitro and in vivo. Mol Cancer Ther 6, 2003-2011.
40. Rosanò L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, and Bagnato A (2007). Combined targeting of endothelin A receptor and epidermalgrowth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 67, 6351-6359.
41. Vacca F, Bagnato A, Catt KJ, and Tecce R (2000). Transactivation of the epidermalgrowth factor receptor in endothelin-1-induced mitogenic signaling inhuman ovarian carcinoma cells. Cancer Res 60, 5310-5317.
42. Rayhman O, Klipper E, Muller L, Davidson B, Reich R, and Meidan R (2008). Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibitendothelin-1 synthesis and the invasive phenotype of ovarian carcinomacells. Cancer Res 68, 9265-9273.
43. Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, Natali PG, and Bagnato A (2000). Role of endothelin-1 in neovascularization of ovariancarcinoma. Am J Pathol 157, 1537-1547.
44. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, and Natali PG (1999). Expression of endothelin 1 and endothelin A receptorin ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59, 720-727.
45. Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, and Catt KJ (1995). Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinomacells. Clin Cancer Res 1, 1059-1066.
46. Moraitis S, Langdon SP, and Miller WR (1997). Endothelin expression and responsivenessin human ovarian carcinoma cell lines. Eur J Cancer 33, 661-668.
47. Moraitis S, Miller WR, Smyth JF, and Langdon SP (1999). Paracrine regulationof ovarian cancer by endothelin. Eur J Cancer 35, 1381-1387.
48. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, and Bagnato A (2009). β-Arrestin links endothelin Areceptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106, 2806-2811.
49. Lalich M, McNeel DG, Wilding G, and Liu G (2007). Endothelin receptorantagonists in cancer therapy. Cancer Invest 25, 785-794.
50. Bagnato A and Rosanò L (2008). The endothelin axis in cancer. Int J Biochem Cell Biol 40, 1443-1451.
51. Kusuhara M, Yamaguchi K, Nagasaki K, Hayashi C, Suzaki A, Hori S, Handa S, Nakamura Y, and Abe K (1990). Production of endothelin in human cancer celllines. Cancer Res 50, 3257-3261.
52. Lahav R (2005). Endothelin receptor B is required for the expansion of melanocyteprecursors and malignant melanoma. Int J Dev Biol 49, 173-180.
53. Morbidelli L, Orlando C, Maggi CA, Ledda F, and Ziche M (1995). Proliferationand migration of endothelial cells is promoted by endothelins via activationof ETB receptors. Am J Physiol 269(2 pt 2), H686-H695.
54. Ziche M, Morbidelli L, Donnini S, and Ledda F (1995). ETB receptors promoteproliferation and migration of endothelial cells. J Cardiovasc Pharmacol 26(suppl 3), S284-S286.
55. Knowles J, Loizidou M, and Taylor I (2005). Endothelin-1 and angiogenesis incancer. Curr Vasc Pharmacol 3, 309-314.
56. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, and Bagnato A (2000). Endothelin-1 induces an angiogenic phenotype in cultured endothelialcells and stimulates neovascularization in vivo. Am J Pathol 157, 1703-1711.
57. Egidy G, Juillerat-Jeanneret L, Jeannin J-F, Korth P, Bosman FT, and Pinet F (2000). Modulation of human colon tumor-stromal interactions by the endothelinsystem. Am J Pathol 157, 1863-1874.
58. Bagnato A, Spinella F, and Rosanò L (2005). Emerging role of the endothelinaxis in ovarian tumor progression. Endocr Relat Cancer 12, 761-772.
59. Spinella F, Rosanò L, Di Castro V, Natali PG, and Bagnato A (2002). Endothelin-1induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J Biol Chem 277, 27850-27855.
60. Rubanyi GMand Polokoff MA (1994). Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46, 325-415.
61. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, et al. (2008). Pharmacology of macitentan, an orally active tissue targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327, 736-745.
62. Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, and Sood AK (2005). Antivascular therapy for orthotopic human ovarian carcinomathrough blockade of the vascular endothelial growth factor and epidermalgrowth factor receptors. Clin Cancer Res 11, 4923-4933.
63. Bénard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, and Riou G (1985). Characterization of a human ovarian adenocarcinoma line, IGROV1, intissue culture and in nude mice. Cancer Res 45, 4970-4979.
64. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, and Fidler IJ (2003). Tissue-specific microvascular endothelial cell lines from H-2K(b)-ts A58 mice for studies of angiogenesis and metastasis. Cancer Res 63, 2971-2976.
65. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, and Coukos G (2008). Endothelin B receptor mediates the endothelial barrier to T cell homing totumors and disables immune therapy. Nat Med 14, 28-36.
66. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, and Birrer MJ (2004). Whole genome expression profiling of advancestage papillary serous ovarian cancer reveals activated pathways. Oncogene 23, 8065-8077.
67. Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, and Santin AD (2007). Gene expression profile of ovarianserous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol 196, 245.e1-245.e11.
68. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor S, Nelson JB, and Pflug BR (2006). Endothelin receptor A blockade enhancestaxane effects in prostate cancer. Neoplasia 8, 725-732.
69. Aubert JD and Juillerat-Jeanneret L (2009). Therapeutic potential of endothelinreceptor modulators: lessons from human clinical trials. Expert Opin Ther Targets 13, 1069-1084.
70. Thakkar SG, Chouveiri TK, and Garcia JA (2006). Endothelin receptor antagonists:rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep 8, 108-113.
71. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, and Dawson NA (2009). Safety and efficacy of the specific endothelin-A receptorantagonist ZD4054 in patients with hormone-resistant prostate cancer and bonemetastases who were pain free or mildly symptomatic: a double-blind, placebocontrolled, randomized, phase 2 trial. Eur Urol 55, 1112-1123.
72. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, et al. (2007). A phase II study of Bosentan, a dual endothelin receptor antagonist, as monotherapy in patients withstage IV metastatic melanoma. Invest New Drugs 25, 247-252.
73. Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE, and Yanagisawa M (1994). Interaction of endothelin-3 with endothelin-B receptor isessential for development of epidermal melanocytes and enteric neurons: missensemutation of endothelin-3 gene in lethal spotting mice. Cell 79, 1277-1285.
74. Demunter A, de Wolf-Peters C, Degreef H, Stas M, and van den Oord JJ (2001). Expression of the endothelin-B receptor in pigment cell lesions of theskin: evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 438, 485-491.
75. Kefford R, Clingan PR, Brady B, Ballmer A, Morganti A, and Hersey P (2010). A randomized, double-blind, placebo-controlled study of high-dose bosentan inpatients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer 9, 69.
76. Sauvageau S, Thorin E, Caron A, and Dupuis J (2007). Endothelin-1-inducedpulmonary vasoreactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 44, 375-381.
77. Porter KE, Olojugba DH, Masood I, Pemberton M, Bell PRF, and London NJM (1998). Endothelin-B receptors mediate intimal hyperplasia in an organculture of human saphenous vein. J Vasc Surg 28, 695-701.
78. Muller DN, Mervaala EMA, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Löffler BM, Ganten D, Schneider W, et al. (2000). Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organdamage. Hypertension 36, 282-290.
79. Rosanò L, Di Castro V, Spinella F, Decandia S, Natali PG, and Bagnato A (2006). ZD4054, a potent endothelin receptor A antagonist, inhibits ovariancarcinoma cell proliferation. Exp Biol Med 231, 1132-1135.
80. Smollich M, Götte M, Fischgräbe J, Macedo LF, Brodie A, Chen S, Radke I, Kiesel L, and Wülfing P (2010). ETAR antagonist ZD4054 exhibits additiveeffects with aromatase inhibitors and fulvestrant in breast cancer therapy and improves in vivo efficacy of anastrozole. Breast Cancer Res Treat 123, 345-357.
81. Rosanò L, Spinella F, Di Castro V, Dedhar S, Nicotra MR, Natali PG, and Bagnato A (2006). Integrin-linked kinase functions as a downstream mediatorof endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther 5, 833-843.
82. Bagnato A, Tecce R, DiCastro V, and Catt KJ (1997). Activation of mitogenic signalingby endothelin 1 in ovarian carcinoma cells. Cancer Res 57, 1306-13011.
83. Del Bufalo D, Di Castro V, Biroccio A, Salani D, Rosanò L, Spinella F, and Bagnato A (2002). Endothelin-1 acts as a survival factor in ovarian carcinomacells. Clin Sci (Lond) (suppl 48), 302S-305S.
84. Lefkowitz RJ and Shenoy SK (2005). Transduction of receptor signals by β-arrestin. Science 308, 512-517.
85. Yokoi K, Kim SJ, Thaker P, Yazici S, Nam DH, He J, Chiao PJ, Sclabas GM, Abbruzzese JL, Hamilton SR, et al. (2005). Induction of apoptosis in tumorassociatedendothelial cells and therapy of orthotopic human pancreatic carcinomain nude mice. Neoplasia 7, 696-704.
86. Yazici S, Kim SJ, Busby JE, He J, Thaker P, Yokoi K, Fan D, and Fidler IJ (2005). Dual inhibition of the epidermal growth factor receptor and vascularendothelial growth factor phosphorylation for antivascular therapy of humanprostate cancer in the prostate of nude mice. Prostate 65, 203-215.
87. Kim SJ, Uehara H, Yazici S, Busby JE, He J, Maya M, Logothetis CJ, Mathew P, Wang X, Do KA, et al. (2006). Targeting platelet-derived growth factor receptoron endothelial cells of multidrug resistant prostate cancer. J Natl Cancer Inst 98, 783-793.